# Centre for Addiction and Mental Health: Phase 1 study closed enrollment, 18 enrolled (Treatment Resistant Depression, Autism Spectrum Disorder)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Centre for Addiction and Mental Health |
| Sponsor type | Academic and hospital |
| Study | Psilocybin for Treatment-Resistant Depression in Autism |
| NCT ID | NCT06731621 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Treatment Resistant Depression; Autism Spectrum Disorder |
| Intervention types | drug |
| Target enrollment | 18 |
| Site countries | Canada |
| Posted | 2024-12-12 |
| Planned start | 2024-11-01 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-26 |
| Last update posted | 2026-10-26 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06731621). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.